Skip to main content

RAD June 2021 Virtual Conference Abstracts & Posters

Abstracts have been published in the September 2021 issue of the British Journal of Dermatology and can be found here:

#476 - Rapid Skin Improvement With Upadacitinib With or Without Topical Corticosteroids (TCS) in Moderate-to-Severe Atopic Dermatitis (AD): Results From 3 Phase 3 Studies (Measure Up 1, Measure Up 2, and AD Up)

Eric L Simpson, MD; Richard B Warren, MBChB, MD; Lawrence F Eichenfield, MD; Norito Katoh, MD, PhD; Xiaofei Hu, PhD; Jiewei Zeng, PhD; Brian M Calimlim, DrPH, MS; Allan R Tenorio, MD; Henrique D Teixeira, PhD; Marjolein De Bruin-Weller, MD, PhD

#477 - Dupilumab Rapidly Improves Atopic Dermatitis Symptoms in Children Aged C ≥ 6 to 12 Years as Measured by POEM

Jonathan I. Silverberg, Lawrence F. Eichenfield, Andreas Wollenberg, Amy Praestgaard, Dimittri Delevry, Ana B. Rossi

#478 - Development of a Bacteriophage Cocktail Targeting Staphylococcus aureus to Treat Atopic Dermatitis

Tamar Lin, Nufar Buchshtab, Yifat Elharar, Julian Nicenboim1 Rotem Edgar, Iddo Weiner, Lior Zelcbuch, Ariel Cohen, Sharon Kredo-Russo, Inbar Gahali-Sass, Naomi Zak, Sailaja Puttagunta, Merav Bassan

#479 - Laboratory Safety of Long-Term Dupilumab Treatment in Adults With Moderate-to-Severe Atopic Dermatitis: Open-Label Extension (OLE) Study

Andrew Blauvelt, Andreas Wollenberg, Lisa A. Beck, Zhen Chen, Jignesh Vakil, Faisal A. Khokhar

#480 - Infections in Adults with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab: Long-Term Data from an Open-Label Extension (OLE) Study

Andrew Blauvelt, Andreas Wollenberg, Lawrence Eichenfield, Zhen Chen, Debra Sierka, Jignesh Vakil, Faisal A. Khokhar, Sonya L. Cyr

#481 - 52-Week Laboratory Safety Findings From an Open-Label Extension (OLE) Study of Dupilumab in Adolescent Patients With Atopic Dermatitis (LIBERTY AD PED-OLE)

Michael J. Cork, Benjamin Lockshin, Andrew Blauvelt, Zhen Chen, Jignesh Vakil, Faisal A. Khokhar

#485 - Dupilumab Provides Early and Sustained Improvement of Sleep Disturbance in Children ≥ 6 Years With Severe Atopic Dermatitis (AD) and Adolescents With Moderate-to-Severe AD

Eric L. Simpson, H. Chih-ho Hong, Danielle Marcoux, Zhen Chen, Gaelle Bégo-Le Bagousse, Jason Wang

#487 - Long-term Dupilumab Treatment up to 100 Weeks Reduces Serum Biomarkers in Adult Patients With Moderate-to-Severe Atopic Dermatitis

Diamant Thaçi, Robert Bissonnette, Mette Deleuran, Sivan Harel, Zhen Chen, Noah A. Levit, Ana B. Rossi

#488 - Laboratory Safety of Dupilumab in Pediatric Patients Aged ≥6 to 12 Years With Severe Atopic Dermatitis: Results From a Phase 3 Trial (LIBERTY AD PEDS)

Andreas Wollenberg, Diamant Thaçi, Michael J. Cork, Peter D. Arkwright, Melinda Gooderham, Xian Sun, Jignesh Vakil, Faisal A. Khokhar

#489 - Upadacitinib Versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis: Analysis of the Heads Up Phase 3 Trial

Andrew Blauvelt, Henrique D. Teixeira, Eric L. Simpson, Antonio Costanzo, Marjolein De Bruin-Weller, Sebastien Barbarot, Vimal H. Prajapati, Peter Lio, Xiaofei Hu, Tianshuang Wu, John Liu, Barry Ladizinski, Alvina D. Chu, Kilian Eyerich

Page 3 of 7
Results 21 - 30 of 65